0001564590-21-055708.txt : 20211109 0001564590-21-055708.hdr.sgml : 20211109 20211109160536 ACCESSION NUMBER: 0001564590-21-055708 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20211109 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211109 DATE AS OF CHANGE: 20211109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MANNKIND CORP CENTRAL INDEX KEY: 0000899460 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133607736 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50865 FILM NUMBER: 211392053 BUSINESS ADDRESS: STREET 1: 30930 RUSSELL RANCH ROAD STREET 2: SUITE 300 CITY: WESTLAKE VILLAGE STATE: CA ZIP: 91362 BUSINESS PHONE: 818-661-5000 MAIL ADDRESS: STREET 1: 30930 RUSSELL RANCH ROAD STREET 2: SUITE 300 CITY: WESTLAKE VILLAGE STATE: CA ZIP: 91362 8-K 1 mnkd-8k_20211109.htm 8-K mnkd-8k_20211109.htm
false 0000899460 0000899460 2021-11-09 2021-11-09

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________

FORM 8-K
_____________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported):  November 9, 2021  

MannKind Corporation
(Exact Name of Registrant as Specified in Charter)

 

Delaware

000-50865

13-3607736

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(I.R.S. Employer Identification Number)

 

30930 Russell Ranch Road, Suite 300, Westlake Village, California 91362

(Address of Principal Executive Offices) (Zip Code)

(818) 661-5000
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.01 per share

 

MNKD

 

The Nasdaq Stock Market LLC

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

On November 9, 2021, MannKind Corporation issued a press release announcing its financial results for the quarter ended September 30, 2021, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02 and the attached exhibit are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01. Financial Statements and Exhibits.

Exhibit 99.1. Press release dated November 9, 2021

Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

MannKind Corporation

 

 

 

Date: November 9, 2021

 

By: 

/s/ David Thomson, Ph.D., J.D.

 

 

 

David Thomson, Ph.D., J.D.

 

 

 

Corporate Vice President, General Counsel and Secretary

 

 

 EX-99.1 2 mnkd-ex991_6.htm EX-99.1 mnkd-ex991_6.htm

 

EXHIBIT 99.1

 


MANNKIND CORPORATION REPORTS
2021 THIRD QUARTER FINANCIAL RESULTS

Conference Call to Begin Today at 5:00 p.m. (ET)

 

•

3Q 2021 Total Revenues of $22.2 million; +45% vs. 3Q 2020

 

•

3Q 2021 Afrezza Net Revenue of $9.8 million; +34% vs. 3Q 2020

 

•

$181.1 million of Cash, Cash Equivalents and Investments at September 30, 2021

 

•

Sale-Leaseback of Danbury manufacturing facility closed November 8, 2021

 

WESTLAKE VILLAGE, Calif., November 9, 2021 (Globe Newswire) -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the quarter and nine months ended September 30, 2021.

“The MannKind team continues to stay focused and execute our corporate objectives of preparing for the commercial launch of Tyvaso DPI, moving our pipeline forward and growing Afrezza,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. “The recently completed animal toxicology studies of inhaled clofazimine support our timeline of moving this unique chemical entity into Phase 1 clinical trials by year-end.”

Third Quarter 2021 Results
Total revenues were $22.2 million for the third quarter of 2021, an increase of $6.9 million or 45% from the same period in 2020, reflecting Afrezza net revenue of $9.8 million and collaboration and services revenue of $12.5 million. Afrezza net revenue increased $2.5 million, or 34%, compared to $7.3 million in the third quarter of 2020 as a result of higher prescription demand and price, including lower gross-to-net deductions. Collaboration and services revenue for the third quarter of 2021 increased $4.4 million, or 54%, compared to the third quarter of 2020 primarily due to additional development work associated with our collaboration with United Therapeutics (“UT”).

Afrezza gross profit for the third quarter of 2021 was $5.9 million compared to $3.7 million in the same period of 2020, a 61% increase that was driven primarily by an increase in Afrezza net revenue. Gross margin in the third quarter of 2021 was 61% compared to 51% for the same period in 2020, reflecting the favorable impact of increased revenue.

Research and development (“R&D”) expenses for the third quarter of 2021 were $3.7 million compared to $1.5 million for the third quarter of 2020. This increase of $2.2 million, or 146%, was attributable to research activities on our product pipeline and to the initiation of the Afrezza pediatrics clinical study (INHALE-1).

Selling, general and administrative (“SG&A”) expenses for the third quarter of 2021 were $17.2 million compared to $13.9 million for the third quarter of 2020, an increase of $3.3 million, or 24%. The increase was primarily attributable to promotional expenses and patient support services of $2.0 million as well as personnel-related expenses of $2.6 million, which was driven by increased stock-based compensation and additional headcount to support Afrezza growth. The spending in SG&A in the third quarter of 2021 was partially offset by a reduction for the promotional cost for Thyquidity that was recognized as cost of revenue — collaboration and services in 2021.

For the third quarter of 2021, the gain on foreign currency translation for insulin purchase commitments denominated in Euros was $2.1 million compared to a loss of $3.9 million for the third quarter of 2020. The fluctuation was due to the change in the U.S. dollar to Euro foreign currency exchange rate.

Interest expense on debt for the third quarter of 2021 was $2.8 million compared to $2.4 million for the third quarter of 2020. This increase of $0.4 million was the result of interest on the $230.0 million 2.5% senior convertible notes issued in the first quarter of 2021, partially offset by a decrease in interest due to the repayment of $35.1 million of outstanding principal under the Mann Group non-convertible promissory note and the repayment of $10.0 million outstanding principal under the MidCap credit facility in the second quarter of 2021. In addition, we reduced the interest rates on the outstanding principal balances under the MidCap credit facility and the Mann Group convertible note through amendments to the respective agreements in the second quarter of 2021.

Gain on extinguishment of debt, a non-cash item, for the three months ended September 30, 2021 was $4.9 million as a result of the Small Business Association’s (the “SBA”) forgiveness of our PPP loan in July 2021.  

The net loss for the third quarter of 2021 was $4.4 million, or $0.02 per share, compared to $11.3 million in the third quarter of 2020, or $0.05 per share. The decreased net loss of $6.8 million was primarily due to an increase in Afrezza net revenues and revenues from collaboration and services, as well as a non-cash gain on the extinguishment of the PPP loan, partially offset by an increase in the cost of revenue from collaboration and services and of SG&A expenses. Non-GAAP net loss, adjusted to exclude the PPP loan debt extinguishment was $9.4 million, or $0.04 per share, for the three months ended September 30, 2021 compared to $11.3 million, or $0.05 per share, for the prior year period.

Nine Months September 30, 2021
Total revenues were $62.9 million for the nine months ended September 30, 2021, an increase of $16.2 million or 35% from the same period in 2020, reflecting Afrezza net revenue of $27.8 million and collaboration and services revenue of $35.1 million.  Afrezza net revenue increased 25% compared to $22.3 million for the nine months ended September 30, 2020, as a result of higher prescription demand, the negative effects of the COVID-19 pandemic in the prior year period, a more favorable mix of Afrezza cartridges, and price including lower gross-to-net deductions. Collaboration and services revenue for the nine months ended September 30, 2021 increased $10.7 million, or 44%, compared to the nine months ended September 30, 2020, primarily due to additional development work associated with our collaboration with UT.

Afrezza gross profit for the nine months ended September 30, 2021 was $15.3 million compared to $10.8 million in the same period of 2020, a 41% increase that was driven primarily by an increase in Afrezza net revenue. Cost of goods sold increased $1.1 million compared to the same period in 2020, primarily due to a $2.0 million fee for an amendment of our insulin supply agreement and a $1.1 million decrease in manufacturing activities which resulted in a lower amount of costs capitalized to inventory, partially offset by $0.9 million of costs associated with lower manufacturing cost per unit and the termination of the free goods program in December 2020. Gross margin for the nine months ended September 30, 2021 was 55% compared to 49% for the same period in 2020. On a non-GAAP basis, which excludes the $2.0 million insulin supply amendment fee, gross margin was 62% for the nine months ended September 30, 2021 compared to 49% for the same period in 2020, reflecting the favorable impact of increased revenue.

R&D expenses for the nine months ended September 30, 2021 were $8.4 million compared to $4.7 million for the nine months ended September 30, 2020. This increase of $3.7 million, or 79%, was attributable to costs incurred for research activities on the product pipeline and to the initiation of the INHALE-1 study as well as personnel costs associated with additional headcount.

SG&A expenses for the nine months ended September 30, 2021 were $54.7 million compared to $41.9 million for the nine months ended September 30, 2020, an increase of $12.8 million, or 30%. The increase was primarily attributable to promotional expenses and patient support services of $5.8 million and personnel-related expenses of $8.5 million, which reflected increased stock-based compensation, additional headcount to support Afrezza growth and our voluntary reduction in compensation expense in response to the COVID-19 pandemic in the prior year. The spend in selling expenses was partially offset by a reduction related to the co-promotional cost for Thyquidity, which was recognized as cost of revenue – collaborations and services.

An impairment of $1.9 million was recognized for the nine months ended September 30, 2020 for a commitment asset related to the future funding commitments of the MidCap credit facility.

For the nine months ended September 30, 2021, the gain on foreign currency translation for insulin purchase commitments denominated in Euros was $5.0 million compared to a $4.0 million loss for the nine months ended September 30, 2020. The fluctuation was due to the change in the U.S. dollar to Euro foreign currency exchange rate.

Interest expense on debt for the nine months ended September 30, 2021 was $12.4 million compared to $7.1 million for the nine months ended September 30, 2020. This increase of $5.3 million was the result of a $3.7 million milestone obligation achieved in the first quarter of 2021 and interest on the $230.0 million 2.5% senior convertible notes issued in the first quarter of 2021, partially offset by a decrease in interest due to the repayment of $35.1 million of outstanding principal under the Mann Group non-convertible promissory note and the repayment of $10.0 million outstanding principal under the MidCap credit facility in the second quarter of 2021. In addition, we reduced the interest rates on the outstanding principal balances under the MidCap credit facility and the Mann Group convertible note through amendments to the respective agreements in the second quarter of 2021.

Non-cash net loss on extinguishment of debt of $17.2 million for the nine months ended September 30, 2021 consisted of a $22.1 million loss on extinguishment of debt for the amendment to the Mann Group convertible note, which did not result in a change in our financial position, partially offset by a $4.9 million gain on extinguishment of debt as a result of the SBA’s forgiveness of our PPP loan in July 2021.

The net loss for the nine months ended September 30, 2021 was $52.9 million, or $0.21 per share, compared to a $30.8 million net loss in the nine months ended September 30, 2020, or $0.14 per share. The increased net loss of $22.0 million was primarily due to the non-cash loss on extinguishment of the Mann Group convertible note of $22.1 million net of a non-cash gain on extinguishment of the PPP loan of $4.9 million, as well as an increase in SG&A expenses, cost of revenue – collaboration and services, partially offset by an increase in Afrezza net revenues and revenues from collaboration and services. Non-GAAP net loss as adjusted for the $17.2 million net loss on extinguishment of debt and the $2.0 million Amphastar amendment fee was $33.7 million, or $0.14 per share, for the nine months ended September 30, 2021 compared to $30.8 million, or $0.14 per share, for the same period in the prior year.

Cash, cash equivalents, and investments at September 30, 2021 were $181.1 million compared to $67.0 million at December 31, 2020. The increase in cash, cash equivalents and investments was primarily due to the issuance of $230.0 million of 2.5 % senior convertible notes in the first quarter of 2021.

 

Non-GAAP Measures
To supplement our unaudited condensed consolidated financial statements presented under U.S. generally accepted accounting principles (GAAP), we are presenting certain non-GAAP financial measures. We are providing these non-GAAP financial measures to disclose additional information to facilitate the comparison of past and present operations, and they are among the indicators management uses as a basis for evaluating our financial performance. We believe that these non-GAAP financial measures, when

considered together with our GAAP financial results, provide management and investors with an additional understanding of our business operating results, including underlying trends.

 

These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with our unaudited condensed consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that we may exclude for purposes of our non-GAAP financial measures; and we may in the future cease to exclude items that we have historically excluded for purposes of our non-GAAP financial measures. Likewise, we may determine to modify the nature of its adjustments to arrive at our non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by us in this report have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.

The following tables reconcile our gross margin financial measure to a non-GAAP presentation as adjusted for the nonrecurring amendment fee related to an amendment to our Insulin Supply Agreement.

 

 

Nine Months Ended

September 30,

 

 

 

2021

 

 

2020

 

 

$ Change

 

 

% Change

 

Net revenue — Afrezza

 

$

27,828

 

 

$

22,260

 

 

$

5,568

 

 

 

25

%

Less cost of goods sold

 

 

(12,538

)

 

 

(11,432

)

 

$

1,106

 

 

 

10

%

GAAP gross profit — Afrezza

 

 

15,290

 

 

 

10,828

 

 

$

4,462

 

 

 

41

%

Exclude Amphastar amendment fee

 

 

2,000

 

 

 

—

 

 

$

2,000

 

 

*

 

Non-GAAP gross profit — Afrezza

 

$

17,290

 

 

$

10,828

 

 

$

6,462

 

 

 

60

%

Non-GAAP gross margin

 

 

62

%

 

 

49

%

 

 

 

 

 

 

 

 

____________________
* Not meaningful

The following tables reconcile our financial measure for net loss and EPS as reported in our condensed consolidated statement of operations to a non-GAAP presentation as adjusted for the $4.9 million non-cash gain on extinguishment of the PPP loan for the three months ended September 30, 2021 and the $22.1 million non-cash loss on extinguishment of the Mann Group convertible note and the $4.9 million gain on extinguishment of the PPP loan for the nine months ended September 30, 2021, which did not result in a change in our financial position, as well as the $2.0 million Amphastar amendment fee.

 

Three Months Ended

September 30,

 

(In thousands, except per share data)

 

2021

 

 

2020

 

 

$ Change

 

 

% Change

 

GAAP to Non-GAAP Net Loss and EPS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(4,426

)

 

$

(11,255

)

 

$

(6,829

)

 

 

(61

%)

Net loss per share - basic and diluted

 

$

(0.02

)

 

$

(0.05

)

 

$

(0.03

)

 

 

(60

%)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Less non-cash loss on extinguishment of debt(1)

 

 

(4,930

)

 

 

—

 

 

$

(4,930

)

 

*

 

Non-GAAP net loss

 

$

(9,356

)

 

$

(11,255

)

 

$

(1,899

)

 

 

(17

%)

Non-GAAP net loss per share - basic and diluted

 

$

(0.04

)

 

$

(0.05

)

 

$

(0.01

)

 

 

(20

%)

Shares used to compute non-GAAP net loss per share

   - basic and diluted

 

 

249,910

 

 

 

229,668

 

 

 

20,242

 

 

 

9

%

 

 

 

Nine Months Ended

September 30,

 

 

 

2021

 

 

2020

 

 

$ Change

 

 

% Change

 

GAAP to Non-GAAP Net Loss and EPS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(52,865

)

 

$

(30,829

)

 

$

22,036

 

 

 

71

%

Net loss per share - basic and diluted

 

$

(0.21

)

 

$

(0.14

)

 

$

0.07

 

 

 

50

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Less non-cash loss on extinguishment of debt, net(1)

 

 

17,200

 

 

 

—

 

 

$

17,200

 

 

*

 

Less Amphastar amendment fee(1)

 

 

2,000

 

 

 

—

 

 

$

2,000

 

 

*

 

Non-GAAP net loss

 

$

(33,665

)

 

$

(30,829

)

 

$

2,836

 

 

 

9

%

Non-GAAP net loss per share - basic and diluted

 

$

(0.14

)

 

$

(0.14

)

 

$

—

 

 

 

0

%

Shares used to compute non-GAAP net loss per share

   - basic and diluted

 

 

248,624

 

 

 

218,559

 

 

 

30,065

 

 

 

14

%

____________________
* Not meaningful
(1)   There is no provision for income taxes associated with the non-cash net loss on extinguishment of debt or the Amphastar amendment fee as a result of our full valuation allowance.

Conference Call
MannKind will host a conference call and presentation webcast to discuss these results today at 5:00 p.m. Eastern Time. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at www.mannkindcorp.com under Events & Presentations.  A replay will be available on MannKind's website for 14 days.

About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.  Afrezza is also available by prescription in Brazil where it is commercialized by the Company’s partner Biomm SA.  MannKind was established in 1991 and is headquartered in Westlake Village, Calif., and has a manufacturing and R&D facility in Danbury, Conn. The Company also employs field sales and medical representatives across the U.S. Please visit www.mannkindcorp.com to learn more.

Forward-Looking Statements
Statements in this press release that are not statements of historical fact are forward-looking statements that involve risks and uncertainties.  These statements include, without limitation, statements regarding the potential approval and commercial launch of Tyvaso DPI, MannKind’s future commercial growth and pipeline advancement, and MannKind’s ability to directly commercialize pharmaceutical products. Words such as “believes”, “anticipates”, “plans”, “expects”, “intend”, “will”, “goal”, “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that Tyvaso DPI may not be approved by the FDA on the timeline expected, or at all, risks associated with product commercialization, risks associated with developing product candidates, risks associated with MannKind’s ability to manage its existing cash resources or raise additional cash resources, the impact of the COVID-19 pandemic, stock price volatility and other risks detailed in MannKind’s filings with the Securities and Exchange Commission, including under the “Risk Factors” heading of its Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent periodic reports on Form 10-Q and current reports on Form 8-K, each as filed with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements

are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

Tyvaso DPI is an investigational combination product that is not approved for any use in any country.  The Tyvaso DPI tradename is pending final FDA review.

TYVASO DPI is a registered trademark of United Therapeutics Corporation.

THYQUIDITY is a registered trademark of Vertice Pharma.

AFREZZA is a registered trademark of MannKind Corporation.

MannKind Contact:
Rose Alinaya, Investor Relations

(818) 661-5000

Email: ir@mannkindcorp.com

 


 

MANNKIND CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands, except share and per share data)

September 30, 2021

 

 

December 31, 2020

 

ASSETS

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

Cash and cash equivalents

$

51,740

 

 

$

67,005

 

Restricted cash

 

—

 

 

 

158

 

Short-term investments

 

87,312

 

 

 

—

 

Accounts receivable, net

 

9,445

 

 

 

4,218

 

Inventory

 

7,482

 

 

 

4,973

 

Prepaid expenses and other current assets

 

3,227

 

 

 

3,122

 

Total current assets

 

159,206

 

 

 

79,476

 

Property and equipment, net

 

30,848

 

 

 

25,867

 

Long-term investments

 

42,059

 

 

 

—

 

Other assets

 

6,094

 

 

 

3,265

 

Total assets

$

238,207

 

 

$

108,608

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' DEFICIT

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

Accounts payable

$

9,528

 

 

$

5,582

 

Accrued expenses and other current liabilities

 

20,829

 

 

 

19,707

 

PPP loan — current

 

—

 

 

 

4,061

 

Deferred revenue — current

 

14,016

 

 

 

33,275

 

Recognized loss on purchase commitments — current

 

5,660

 

 

 

11,080

 

Total current liabilities

 

50,033

 

 

 

73,705

 

Senior convertible notes

 

223,580

 

 

 

—

 

MidCap credit facility

 

38,723

 

 

 

49,335

 

Mann Group promissory notes

 

18,425

 

 

 

63,027

 

Accrued interest — Mann Group promissory notes

 

286

 

 

 

4,150

 

PPP loan — long term

 

—

 

 

 

812

 

2024 convertible notes

 

—

 

 

 

5,000

 

Recognized loss on purchase commitments — long term

 

79,653

 

 

 

84,208

 

Operating lease liability

 

798

 

 

 

1,202

 

Deferred revenue  — long term

 

1,552

 

 

 

1,662

 

Milestone rights liability

 

4,838

 

 

 

5,926

 

Deposits from customer

 

5,007

 

 

 

—

 

Total liabilities

 

422,895

 

 

 

289,027

 

 

 

 

 

 

 

 

 

Stockholders' deficit:

 

 

 

 

 

 

 

Undesignated preferred stock, $0.01 par value — 10,000,000 shares authorized;

   no shares issued or outstanding as of September 30, 2021 and December 31, 2020

 

—

 

 

 

—

 

Common stock, $0.01 par value - 400,000,000 shares authorized,

   250,245,831 and 242,117,089 shares issued and outstanding

   at September 30, 2021 and December 31, 2020, respectively

 

2,502

 

 

 

2,421

 

Additional paid-in capital

 

2,914,818

 

 

 

2,866,303

 

Accumulated deficit

 

(3,102,008

)

 

 

(3,049,143

)

Total stockholders' deficit

 

(184,688

)

 

 

(180,419

)

Total liabilities and stockholders' deficit

$

238,207

 

 

$

108,608

 

 


 

MANNKIND CORPORATION AND SUBSIDIARIES  
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except per share data)

Three Months Ended

September 30,

 

 

Nine Months Ended

September 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net revenue — commercial product sales

$

9,753

 

 

$

7,275

 

 

$

27,828

 

 

$

22,260

 

Revenue — collaborations and services

 

12,458

 

 

 

8,077

 

 

 

35,099

 

 

 

24,441

 

Total revenues

 

22,211

 

 

 

15,352

 

 

 

62,927

 

 

 

46,701

 

Expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

3,812

 

 

 

3,591

 

 

 

12,538

 

 

 

11,432

 

Cost of revenue — collaborations and services

 

6,075

 

 

 

1,581

 

 

 

14,885

 

 

 

6,926

 

Research and development

 

3,655

 

 

 

1,484

 

 

 

8,426

 

 

 

4,703

 

Selling, general and administrative

 

17,221

 

 

 

13,899

 

 

 

54,690

 

 

 

41,919

 

Asset impairment

 

106

 

 

 

—

 

 

 

106

 

 

 

1,889

 

(Gain) loss on foreign currency translation

 

(2,068

)

 

 

3,927

 

 

 

(5,003

)

 

 

3,998

 

Loss on purchase commitments

 

—

 

 

 

—

 

 

 

339

 

 

 

—

 

Total expenses

 

28,801

 

 

 

24,482

 

 

 

85,981

 

 

 

70,867

 

Loss from operations

 

(6,590

)

 

 

(9,130

)

 

 

(23,054

)

 

 

(24,166

)

Other (expense) income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

36

 

 

 

18

 

 

 

64

 

 

 

165

 

Interest expense on notes

 

(2,709

)

 

 

(1,057

)

 

 

(10,943

)

 

 

(3,212

)

Interest expense on Mann Group promissory notes

 

(94

)

 

 

(1,318

)

 

 

(1,492

)

 

 

(3,858

)

Gain (loss) on extinguishment of debt, net

 

4,930

 

 

 

—

 

 

 

(17,200

)

 

 

—

 

Other income (expense)

 

1

 

 

 

14

 

 

 

(240

)

 

 

24

 

Total other income (expense)

 

2,164

 

 

 

(2,343

)

 

 

(29,811

)

 

 

(6,881

)

Loss before provision for income taxes

 

(4,426

)

 

 

(11,473

)

 

 

(52,865

)

 

 

(31,047

)

Provision for income taxes

 

—

 

 

 

218

 

 

 

—

 

 

 

218

 

Net loss

$

(4,426

)

 

$

(11,255

)

 

$

(52,865

)

 

$

(30,829

)

Net loss per share - basic and diluted

$

(0.02

)

 

$

(0.05

)

 

$

(0.21

)

 

$

(0.14

)

Shares used to compute net loss per share - basic and diluted

 

249,910

 

 

 

229,668

 

 

 

248,624

 

 

 

218,559

 

 

 GRAPHIC 3 gw4mxtotiw0h000001.jpg GRAPHIC begin 644 gw4mxtotiw0h000001.jpg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end EX-101.SCH 4 mnkd-20211109.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 mnkd-20211109_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 6 mnkd-20211109_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 mnkd-8k_20211109_htm.xml IDEA: XBRL DOCUMENT 0000899460 2021-11-09 2021-11-09 false 0000899460 8-K 2021-11-09 MannKind Corporation DE 000-50865 13-3607736 30930 Russell Ranch Road Suite 300 Westlake Village CA 91362 (818) 661-5000 false false false false false Common Stock, par value $0.01 per share MNKD NASDAQ XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Nov. 09, 2021
Cover [Abstract]  
Entity Registrant Name MannKind Corporation
Amendment Flag false
Entity Central Index Key 0000899460
Document Type 8-K
Document Period End Date Nov. 09, 2021
Entity Incorporation State Country Code DE
Entity File Number 000-50865
Entity Tax Identification Number 13-3607736
Entity Address, Address Line One 30930 Russell Ranch Road
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Westlake Village
Entity Address, State or Province CA
Entity Address, Postal Zip Code 91362
City Area Code (818)
Local Phone Number 661-5000
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.01 per share
Trading Symbol MNKD
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.mannkindcorp.com/20211109/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports mnkd-8k_20211109.htm mnkd-20211109.xsd mnkd-20211109_lab.xml mnkd-20211109_pre.xml mnkd-ex991_6.htm http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mnkd-8k_20211109.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "mnkd-8k_20211109.htm" ] }, "labelLink": { "local": [ "mnkd-20211109_lab.xml" ] }, "presentationLink": { "local": [ "mnkd-20211109_pre.xml" ] }, "schema": { "local": [ "mnkd-20211109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mnkd", "nsuri": "http://www.mannkindcorp.com/20211109", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "mnkd-8k_20211109.htm", "contextRef": "C_0000899460_20211109_20211109", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.mannkindcorp.com/20211109/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "mnkd-8k_20211109.htm", "contextRef": "C_0000899460_20211109_20211109", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mannkindcorp.com/20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mannkindcorp.com/20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mannkindcorp.com/20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mannkindcorp.com/20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mannkindcorp.com/20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mannkindcorp.com/20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mannkindcorp.com/20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mannkindcorp.com/20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mannkindcorp.com/20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mannkindcorp.com/20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mannkindcorp.com/20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mannkindcorp.com/20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mannkindcorp.com/20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mannkindcorp.com/20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mannkindcorp.com/20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mannkindcorp.com/20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mannkindcorp.com/20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mannkindcorp.com/20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mannkindcorp.com/20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mannkindcorp.com/20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mannkindcorp.com/20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mannkindcorp.com/20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mannkindcorp.com/20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001564590-21-055708-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-055708-xbrl.zip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